The Food and Drug Administration has granted approval to Invokana, a Type 2 diabetes drug manufactured by a unit of Johnson & Johnson (NYSE:JNJ). The drug is part of a new class of treatments known as SGLT2 inhibitors aimed at lowering blood sugar in patients with that form of the disease.
With its approval, the FDA has mandated that five postmarketing studies be conducted for the drug, which was developed by J&J subsidiary Janssen Pharmaceuticals.
Type 2 is by far the most common variety of diabetes, affecting roughly 24 million people. According to the FDA, it comprises more than 90% of the diabetes cases diagnosed in this country.
Fool contributor Eric Volkman has no position in Johnson & Johnson. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Dividend Stocks That Pay Out Over $8 Billion a Year
Can these huge companies keep the big dividend bucks flowing?
Johnson & Johnson Aims to Start 2018 Healthy
Investors have high hopes for the healthcare conglomerate.
Is Johnson & Johnson a Buy?
Is now a good time to invest in the healthcare titan's stock?